Sign in Subscribe
Chronic kidney failure

Urine Biomarkers Hold Promise for Early Detection and Treatment of Chronic Kidney Disease

Strategic Insights

— 2 min read

Researchers have identified urinary biomarkers as a potential solution for early detection, prognostication, and therapeutic guidance in chronic kidney disease (CKD). According to a recent study published in Nature Reviews Nephrology, albuminuria and estimated glomerular filtration rate (eGFR) are the main diagnostic and monitoring metrics used in CKD, but they represent the consequence rather than the cause of the disease. In contrast, urinary biomarkers such as nucleotides, proteins, peptides, and metabolites can provide valuable information about kidney-tissue biology and pathological processes, making them a promising source of biomarkers for early disease detection and treatment.

Key Takeaways:

  • The study highlighted the limitations of current diagnostic and monitoring metrics in CKD, which can neither detect disease at its earliest stages nor determine its aetiology.
  • Urinary biomarkers have the potential to improve disease management by providing a wealth of information about kidney-tissue biology and pathological processes.
  • The current research is dominated by studies of protein biomarkers that reflect tissue injury and repair, inflammation, and fibrosis, but data on biomarkers for guiding therapy are scarce.
  • The clinical implementation of urinary biomarkers is limited by the paucity of clinical and health-economic impact data, especially data on the combined use of urinary biomarkers and the latest therapies available for people with CKD.
  • The study emphasized the urgent need for more targeted studies on biomarkers for guiding therapy, given the availability of several new therapies that are effective in attenuating CKD progression and improving patient outcomes.
  • The research was conducted at the Academy of Athens in Greece, led by Antonia Vlahou and her team at the Center of Systems Biology, Biomedical Research Foundation.
  • The study was published in Nature Reviews Nephrology, a leading peer-reviewed journal in the field of nephrology.

Statistics:

  • The study states that albuminuria and eGFR are the main diagnostic and monitoring metrics used in CKD, but they can neither detect disease at its earliest stages nor determine its aetiology.
  • Urinary biomarkers can provide a wealth of information about kidney-tissue biology and pathological processes, making them a promising source of biomarkers for early disease detection and treatment.
  • The study highlights the urgent need for more targeted studies on biomarkers for guiding therapy, with a emphasis on the combined use of urinary biomarkers and the latest therapies available for people with CKD.
  • The study was conducted at the Academy of Athens in Greece, where Antonia Vlahou and her team are based at the Center of Systems Biology, Biomedical Research Foundation.
  • The study was published in Nature Reviews Nephrology, a leading peer-reviewed journal in the field of nephrology.

Sources:

  • NewsRx. Studies Conducted at Academy of Athens on Chronic Kidney Disease Recently Reported (Urine as a source of biomarkers and biological knowledge in chronic kidney disease). Health & Medicine Week. October 24, 2025; p 6875.
  • Urine as a source of biomarkers and biological knowledge in chronic kidney disease. Nature Reviews Nephrology, 2025.
  • Nature Portfolio, Heidelberger Platz 3, Berlin, 14197, Germany.
  • Antonia Vlahou, Center of Systems Biology, Biomedical Research Foundation, Academy of Athens, Athens, Greece.

Read more